Navigation Links
Topokine Announces Dosing of First Subject in a Phase I Clinical Trial of XAF5 Gel for Local Reduction of Subcutaneous Fat
Date:12/5/2012

Newton, MA (PRWEB) December 05, 2012

Topokine Therapeutics has announced that the first subject has been dosed in a repeat-dose, healthy volunteer study of XAF5 Gel, a skin cream for local reduction of excess subcutaneous fat (lipohypertrophy). The study is assessing the safety and tolerability of repeat doses of XAF5 Gel at three concentrations. The study is also quantifying the effects of XAF5 on subcutaneous adipose tissue.

“We are excited to enter clinical development with the first non-invasive, local drug therapy to reduce lipohypertrophy,” said Topokine’s Chief Scientific Officer, Michael Singer, MD, PhD. “We hope to provide a convenient and effective alternative to surgery and injections.”

XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors. XAF5 reduces adipose tissue in vivo without inflammation or necrosis.

“Topokine’s preclinical data are promising,” said Jeffrey S. Dover, MD, FRCPC, a nationally recognized dermatologist and member of the Company’s Scientific Board of Advisors. “A skin cream that reduces subcutaneous fat would be an attractive proposition for patients and physicians alike.”

The company expects to report top-line results in the first half of 2013.

About Topokine and XAF5 Gel
Topokine Therapeutics is a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics. The company's lead program, XAF5 Gel, is a skin cream being developed for local reduction of excess subcutaneous fat. XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors. XAF5 reduces adipose tissue in vivo without inflammation or necrosis.

Forward-Looking Statements
This press release contains forward-looking statements regarding the development of XAF5. These statements are based on Topokine’s current beliefs and expectations, but actual results may differ.

Read the full story at http://www.prweb.com/releases/2012/12/prweb10203404.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform
2. Chemical Publishing Company Announces its Niche Catalog in the Water Technology and Water Treatment Space
3. Japan Bioinformatics Announces Study on Leading Mapping Tools for DNA Mutation Discovery
4. The Scientist Proudly Announces the Top 10 Innovations of 2012
5. Bayer CropScience Announces LibertyLink LinkUp Offer Increased for 2013 Season
6. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
7. Genomic Health Announces Presentation of Six Studies at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium
8. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
9. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
10. Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinsons Disease
11. BioRestorative Therapies Announces Launch of New Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... 10, 2017 , ... Dr. Bob Harman, founder and CEO of VetStem ... The event entitled “Stem Cells and Their Regenerative Powers,” was held ... Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
(Date:10/9/2017)... ... 09, 2017 , ... The Giving Tree Wellness Center announces ... needs of consumers who are incorporating medical marijuana into their wellness and health ... As operators of two successful Valley dispensaries, The Giving Tree’s two founders, Lilach ...
(Date:10/7/2017)... Oct. 6, 2017  The 2017 Nobel Prize ... scientists, Jacques Dubochet, Joachim Frank and ... cryo-electron microscopy (cryo-EM) have helped to ... structural biology community. The winners worked with systems ... routinely produce highly resolved, three-dimensional images of protein ...
Breaking Biology Technology:
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
Breaking Biology News(10 mins):